Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Merit Medical Systems, Inc. (NASDAQ: MMSI) provide detailed information on the company’s financial condition, operations, risk factors, and material events as a Utah‑incorporated medical device and healthcare technology company. Through Forms 10‑K and 10‑Q, investors can review net sales by segment, gross profit, operating expenses, and other key metrics for Merit’s Cardiovascular and Endoscopy businesses, along with discussions of risks related to regulation, reimbursement, supply chain, acquisitions, and market conditions.
Merit also uses Form 8‑K to report significant developments. Recent 8‑K filings have furnished press releases on quarterly and preliminary revenue results, financial guidance, and non‑GAAP measures such as constant currency revenue, non‑GAAP operating margin, non‑GAAP net income, and non‑GAAP earnings per share. Other 8‑Ks disclose leadership and board changes, including the appointment of a new President and Chief Executive Officer and related compensation arrangements, as well as transitions in board roles.
Additional 8‑K filings document acquisition activity and product updates. Merit has reported signing and closing an asset purchase agreement to acquire the C2 CryoBalloon device and related technology, including the proposed purchase consideration and the expected impact on revenue and earnings measures. The company has also furnished press releases on updates to its WRAPSODY Cell‑Impermeable Endoprosthesis product, including commercialization and reimbursement developments.
On this page, Stock Titan presents Merit’s SEC filings with real‑time updates from EDGAR and AI‑powered summaries that explain the context and key points of each document. Investors can quickly scan annual reports (Form 10‑K), quarterly reports (Form 10‑Q), and current reports (Form 8‑K) to understand segment performance, non‑GAAP reconciliations, acquisition terms, leadership changes, and risk disclosures. Filings related to executive appointments and compensation, as well as transaction‑related disclosures, help users analyze governance and incentive structures alongside the company’s operating and financial trends.
Merit Medical Systems’ Chief Commercial Officer Christian Adam Smith reported multiple equity awards and related tax withholding in company stock. On February 26, 2026, he acquired 8,203, 6,409 and 6,762 shares of common stock at $0 per share through grants and the settlement of performance stock units.
Footnotes state two awards are restricted stock units that vest in scheduled annual installments over two or three years, each RSU converting into one share upon vesting. An additional 2,018 shares were surrendered back to the company at $78.02 per share to cover payroll and income taxes, with no shares sold in the open market.
MERIT MEDICAL SYSTEMS INC CFO and Treasurer Raul Parra Jr. reported multiple equity awards and related tax-share withholding in common stock. On February 26, 2026, he acquired 12,305, 9,613, and 17,002 shares of common stock at $0.00 per share through grants and performance-based vesting.
Footnotes explain that two awards are restricted stock units that vest in scheduled annual installments, and one reflects shares issued after performance stock unit conditions were met. He also surrendered 5,778 shares at $78.02 per share back to the company to cover payroll and income taxes, with no open-market sale.
After these transactions, Parra held 57,343 shares of common stock directly, non-qualified stock options for 9,070 and 13,576 shares, and an additional 2,735 shares indirectly through a 401(k) plan.
Merit Medical Systems files its annual report outlining its role as a global manufacturer of disposable medical devices for cardiology, radiology, oncology, critical care and endoscopy. The company operates cardiovascular and endoscopy segments, sells in more than 40 countries and had about 7,500 employees as of December 31, 2025.
U.S. sales represented 60% of net sales in 2025, while international sales grew 9.1% and accounted for 40%, with China as the largest non-U.S. market but pressured by volume-based procurement price cuts. Merit highlights growth via internal R&D and acquisitions, including deals with Pentax of America, Biolife, Cook Medical, EndoGastric Solutions and AngioDynamics.
The filing details extensive regulatory, reimbursement, geopolitical, supply chain and cost risks, along with completion of a five-year Corporate Integrity Agreement in October 2025. Merit also emphasizes sustainability initiatives and broad workforce, wellness and safety programs supported by ISO 45001 certifications at multiple sites.
Merit Medical Systems reported strong fourth quarter and full year 2025 results and issued higher 2026 guidance. Full year 2025 net sales were $1,515.9 million, up 12% from 2024, with GAAP diluted EPS of $2.13 and non-GAAP EPS of $3.83, both increasing year over year.
Profitability improved as GAAP gross margin rose to 48.7% and non-GAAP gross margin to 53.7%, while GAAP operating margin reached 12.2% and non-GAAP operating margin 20.3%. Free cash flow was $215.7 million, up 16%, supported by $297.4 million in operating cash flow and $81.7 million of capital expenditures.
For 2026, Merit guides revenue to $1.610–$1.630 billion, implying 6%–8% growth, and non-GAAP EPS to $4.01–$4.15, 5%–8% above 2025. Management highlights stable constant-currency growth, improving margins, strong cash generation and continued execution of its multi-year growth initiatives program.
Merit Medical Systems, Inc. reported that it has issued a press release with preliminary unaudited revenue for the quarter ended December 31, 2025 and outlined plans to report full fourth-quarter and full-year 2025 results along with fiscal 2026 guidance.
The company also disclosed significant board changes. Longtime leader Fred P. Lampropoulos resigned as a director and Chair of the Board effective January 4, 2026, after previously concluding his service as Executive Chair, President and Chief Executive Officer, citing personal reasons and with no disagreement related to management, the board, or financial reporting and controls. Merit entered into a three-month consulting agreement with him at $250,000 per month. Effective January 5, 2026, the board appointed former Lead Independent Director F. Ann Millner, Ed.D. as Chair and reduced the board size from eleven to ten members.
Merit Medical Systems' chief operating officer Neil W. Peterson reported an option exercise and share sale in company stock. On January 6, 2026, he exercised 5,000 non-qualified stock options with an exercise price of $54.4 per share, receiving 5,000 shares of common stock. The same day, he sold 5,000 common shares at a price of $90 per share, leaving him with 28,369 common shares held directly afterward. The filing also shows remaining non-qualified stock options for 25,000 shares at an exercise price of $68.33 and 13,576 shares at $70.58, all held directly. The option exercise and related sale were carried out under a Rule 10b5-1 trading plan adopted on November 6, 2024.
The issuer filed a Form 144 indicating that a holder plans to sell 5,000 shares of common stock under Rule 144.
The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/06/2026 and an aggregate market value of $450,000. The filing notes that 59,290,248 shares of this class were outstanding.
The 5,000 shares were acquired on 01/06/2026 via a stock option exercise from the issuer, paid for in cash on the same date.
Merit Medical Systems (MMSI) reported an insider transaction by a director and Executive Chairman. On 11/25/2025, the insider sold 10,000 shares of common stock at a weighted average price of $88.0377, with individual trades between $88.00 and $88.175. After the sale, the insider directly owned 1,019,955 shares of common stock.
The insider also had indirect holdings of 8,280.258 shares through a spouse, 98,132 shares through a 401(k) plan as of 10/31/2025, and 90 shares held by the spouse as custodian for a child. In addition, the insider held non-qualified stock options to purchase 100,334 shares at $37.71 expiring on 02/26/2027, 58,083 shares at $56.25 expiring on 03/19/2028, and 54,302 shares at $70.58 expiring on 02/28/2030, each vesting in 25% annual installments from their respective commencement dates.
Merit Medical Systems (MMSI) Executive Chairman and director reported a sale of company stock and detailed his remaining holdings. On 11/21/2025, he sold 25,000 shares of common stock at a weighted average price of $87.31, with individual trades ranging from $87.0000 to $87.6708. After this sale, he directly owns 1,029,955 shares of Merit Medical common stock.
He also reports indirect ownership of 8,280.258 shares held by his spouse, 98,132 shares held in a 401(k) plan as of 10/31/2025, and 90 shares held by his spouse as custodian for a child, while expressly disclaiming beneficial ownership of the spouse’s securities. In addition, he holds non-qualified stock options to purchase 100,334 shares at $37.71 exercisable through 02/26/2027, 58,083 shares at $56.25 through 03/19/2028, and 54,302 shares at $70.58 through 02/28/2030, each vesting in 25% annual installments from their respective commencement dates.
Merit Medical Systems (MMSI) Executive Chairman and director reported an insider stock sale. On 11/20/2025, the reporting person sold 20,000 shares of Merit Medical common stock at a weighted average price of $85.1325 per share. The filing notes that these shares were sold in multiple transactions within a price range from $85.01 to $86.3499 per share.
After this sale, the reporting person directly owned 1,054,955 shares of common stock. In addition, there were indirect holdings of 8,280.258 shares through a spouse, 98,132 shares through a 401(k) plan as of 10/31/2025, and 90 shares held by a spouse as custodian for a child. The report also lists non-qualified stock options with exercise prices between $37.71 and $70.58 covering a total of 212,719 shares, with vesting in equal 25% annual installments beginning on their respective commencement dates.